Skip to main content

Ionis Pharmaceuticals Inc

IONS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000874015

In the last 90 days, Ionis Pharmaceuticals Inc insiders filed 1 open-market purchase and 4 sales; 515 institutions reported holding it in 13F filings for Q2 2026, worth $14.3B in total; ARK Invest is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Ionis Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $1.06M in total
Open-market sells
4 filings
4 insiders, $3.55M in total
Insiders trading
5
Net value
−$2.49M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Ionis Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Ionis Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Bennett C FrankEVP, Chief Scientific Officer60,128Sep 2, 20268
O'Neil Patrick R.EVP CLO & General Counsel59,205Sep 2, 202610
Monia Brett PChief Executive Officer242,760Sep 2, 202610
Birchler BrianEVP, Corp and Development Ops102,883Sep 2, 20268
Hayden Michael RDirector24,000IndirectJul 31, 20262
Reikes Peter NDirector14,222Jul 17, 20262
Hantson LudwigDirector–Jul 17, 20262
Herman Joan EDirector51,306Jul 17, 20263
Berthelsen Spencer RDirector161,233Jul 17, 20264
Diaz Allene M.Director3,811Jul 9, 20263
Kordasiewicz Holly B.EVP, Chief Development Officer22,096Jul 9, 20264
Yang Michael J.Director7,940Jul 6, 20262
Loscalzo JosephDirector36,330Jul 6, 20264
Klein Joseph IIIDirector11,014Jul 6, 20265
Baroldi JosephEVP, Chief Business Officer4,669IndirectJun 30, 20269
Schneider EugeneEVP, Chf Clinical Develop Ofcr77,114Jun 30, 20265
Swayze EricEVP Research21,759Jun 26, 20269
Parshall B LynneDirector51,344Apr 17, 20263
Jenne KyleEVP, Chf GL Pdt Str Ofcr23,713Apr 17, 20264
Devers Shannon L.EVP, Chief Human Resources Ofc16,348Apr 2, 20268
Hougen Elizabeth LEVP, Finance & CFO82,660Mar 18, 20265
Wender Joseph HDirector36,035IndirectDec 3, 20254
Geary Richard SEVP, Chief Development Officer59,657Nov 7, 20253
Cadoret-Manier OnaizaEVP,Chf GL Pdt Str & Oper Ofc35,788Sep 4, 20240
Muto Frederick TDirector59,597Jul 19, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 5, 2026 (view filing)Mar 3-42 daysLoscalzo JosephDirectorSSale−1.03K$80.27−$82.8K−2.8%36.3K after2 lots10b5-1
Mar 11, 2026 (view filing)Mar 101 dayJenne KyleEVP, Chf GL Pdt Str OfcrSSale−37.3K$75.85−$2.83M−76.1%11.7K after2 lots10b5-1
Mar 11, 2026 (view filing)Mar 9-102 daysMonia Brett PChief Executive OfficerSSale−160.8K$75.35−$12.1M−39.9%242.7K after5 lots10b5-1
Mar 11, 2026 (view filing)Mar 92 daysO'Neil Patrick R.EVP CLO & General CounselSSale−10.1K$75.25−$763.6K−14.0%62.2K after10b5-1
Mar 18, 2026 (view filing)Mar 16-172 daysHougen Elizabeth LEVP, Finance & CFOSSale−225.2K$72.43−$16.3M−73.2%82.7K after3 lots10b5-1
Mar 23, 2026 (view filing)Mar 194 daysSchneider EugeneEVP, Chf Clinical Develop OfcrSSale−5.81K$70.97−$412.5K−8.3%63.9K after10b5-1
Apr 2, 2026 (view filing)Apr 2Same dayDevers Shannon L.EVP, Chief Human Resources OfcSSale−6.19K$74.05−$458.6K−27.5%16.3K after10b5-1
Apr 2, 2026 (view filing)Apr 11 dayKlein Joseph IIIDirectorSSale−22.3K$75.54−$1.69M−67.0%11.0K after2 lots10b5-1
Apr 17, 2026 (view filing)Apr 161 dayBaroldi JosephEVP, Chief Business OfficerSSale−5.62K$74.56−$419.0K−10.8%46.5K after
Apr 17, 2026 (view filing)Apr 161 dayBirchler BrianEVP, Corp and Development OpsSSale−973$75.04−$73.0K−1.4%67.5K after
Apr 17, 2026 (view filing)Apr 161 dayJenne KyleEVP, Chf GL Pdt Str OfcrSSale−4.90K$75.17−$368.5K−17.1%23.7K after
Apr 17, 2026 (view filing)Apr 152 daysParshall B LynneDirectorSSale−5.00K$76.27−$381.4K−8.9%51.3K after2 lots10b5-1
Apr 30, 2026 (view filing)Apr 282 daysBaroldi JosephEVP, Chief Business OfficerSSale−1.63K$71.79−$116.7K−3.5%44.9K after10b5-1
May 5, 2026 (view filing)May 14 daysKlein Joseph IIIDirectorSSale−10.1K$73.51−$743.2K−47.9%11.0K after2 lots10b5-1
May 6, 2026 (view filing)May 42 daysLoscalzo JosephDirectorSSale−77.3K$75.06−$5.80M−68.0%36.3K after2 lots10b5-1
May 15, 2026 (view filing)May 13-142 daysMonia Brett PChief Executive OfficerSSale−4.54K$78.49−$356.0K−1.8%242.7K after2 lots10b5-1
Jun 3, 2026 (view filing)Jun 12 daysBerthelsen Spencer RDirectorSSale−8.00K$75.67−$605.4K−4.9%156.0K after10b5-1
Jun 16, 2026 (view filing)Jun 151 dayBerthelsen Spencer RDirectorSSale−8.00K$73.49−$587.9K−4.9%156.0K after10b5-1
Jun 16, 2026 (view filing)Jun 124 daysKordasiewicz Holly B.EVP, Chief Development OfficerSSale−60.8K$73.40−$4.47M−73.0%22.5K after2 lots10b5-1
Jun 26, 2026 (view filing)Jun 251 daySwayze EricEVP ResearchSSale−10.6K$79.18−$839.5K−32.8%21.8K after10b5-1
Jun 26, 2026 (view filing)Jun 24-262 daysMonia Brett PChief Executive OfficerSSale−85.6K$79.70−$6.83M−25.9%245.6K after3 lots10b5-1
Jun 30, 2026 (view filing)Jun 264 daysSchneider EugeneEVP, Chf Clinical Develop OfcrSSale−26.0K$81.05−$2.11M−25.2%77.1K after10b5-1
Jun 30, 2026 (view filing)Jun 264 daysO'Neil Patrick R.EVP CLO & General CounselSSale−3.07K$80.00−$245.5K−4.8%61.5K after10b5-1
Jun 30, 2026 (view filing)Jun 264 daysBaroldi JosephEVP, Chief Business OfficerSSale−5.63K$80.16−$451.7K−54.7%4.67K after10b5-1
Jul 6, 2026 (view filing)6:49 PM ETJul 15 daysKlein Joseph IIIDirectorSSale−11.5K$79.04−$910.4K−51.1%11.0K after2 lots10b5-1
Jul 9, 2026 (view filing)6:07 PM ETJul 72 daysKordasiewicz Holly B.EVP, Chief Development OfficerSSale−362$84.30−$30.5K−1.6%22.1K after10b5-1
Jul 9, 2026 (view filing)6:07 PM ETJul 72 daysDiaz Allene M.DirectorSSale−10.1K$85.42−$863.6K−72.6%3.81K after10b5-1
Jul 9, 2026 (view filing)7:26 PM ETJul 72 daysBennett C FrankEVP, Chief Scientific OfficerSSale−5.54K$83.58−$462.7K−6.9%75.0K after10b5-1
Jul 9, 2026 (view filing)7:26 PM ETJul 72 daysBennett C FrankEVP, Chief Scientific OfficerSSale−15.0K$85.46−$1.28M−100.0%0 after10b5-1
Jul 31, 2026 (view filing)4:42 PM ETJul 30-311 dayHayden Michael RDirectorPPurchase+20.0K$52.94+$1.06M+500.0%24.0K after2 lots